COMMONWEALTH OF KENTUCKY STATE FISCAL NOTE STATEMENT LEGISLATIVE RESEARCH COMMISSION 2017 REGULAR SESSION

<u>MEASURE</u>			
2017 BR NUMBER <u>0811</u>		HOUSE BILL NUMBER 145	
RESOLUTION NUMBER		AMENDMENT NUMBER	
SUBJECT/TITLE An ACT rela	nting to drug edu	cation.	
SPONSOR Representative Tip	<u>ton</u>		
NOTE SUMMARY			
FISCAL ANALYSIS: IMPACT	☐ NO IMPACT	☐ INDETERMINABLE IMPACT	
LEVEL(S) OF IMPACT: STATE	LOCAL	☐ FEDERAL	
BUDGET UNIT(S) IMPACT: Kentuck	y Department of Ed	<u>lucation</u>	
$FUND(S)\ IMPACT: \ \ \boxtimes\ GENERAL\ \ \Box$	ROAD FEDERA	L 🗌 RESTRICTED AGENCY 🔲 OTHER	
FISCAL SUMMARY			

FISCAL	2016-2017	2017-2018	ANNUAL IMPACT AT FULL
ESTIMATES			IMPLEMENTATION
REVENUES			
EXPENDITURES		\$30,000	
NET EFFECT		(\$30,000)	

^() indicates a decrease/negative

MEASURE'S PURPOSE: The measure's purpose is to include prescription opioid abuse prevention in physical and health education throughout elementary, middle, and high school levels.

PROVISIONS/MECHANICS: Section 1 requires administrative regulations set by the Kentucky Board of Education to include physical and health education instruction in prescription opioid abuse prevention, with an emphasis on the prescription drug epidemic and the connection between prescription opioid abuse and addiction to other drugs.

Section 2 instructs the Office of Drug Control Policy (ODCP) to develop recommendations for the instruction in prescription opioid abuse prevention, and to submit the recommendations to the Kentucky Department of Education (KDE). KDE shall publish the recommendations on its website for use by districts in developing their health curriculum.

FISCAL EXPLANATION: Current standards broadly cover drug prevention education, so adding prescription opioid specific information would be a minor change. With the changes

being minor and affecting an existing course, the fiscal impact would be about half of normal costs, or approximately \$30,000.

Per ODCP, there is no fiscal impact to the ODCP.

DATA SOURCE(S): <u>Kentucky Department of Education</u>, <u>Office of Drug Control Policy PREPARER</u>: <u>Jonathan Eakin NOTE NUMBER</u>: <u>62</u> REVIEW: <u>JRS</u> DATE: <u>2/16/2017</u>

LRC 2017-BR0811-HB145